Citrulline-based assessment score: First choice for measuring and monitoring intestinal failure after high-dose chemotherapy

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1706-1711

  Herbers, A H ^a   Feuth, T ^a   Donnelly, J P ^a   Blijlevens, N M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; Citrulline; Mucositis

Indexed keywords

BUSULFAN; CARMUSTINE; CIPROFLOXACIN; CITRULLINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; IDARUBICIN; MELPHALAN; ONDANSETRON; THYMOCYTE ANTIBODY; VALACICLOVIR;

ADOLESCENT; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INTESTINE MUCOSA; INTESTINE VILLUS ATROPHY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RADIATION DOSE; RISK ASSESSMENT; VOMITING; WHOLE BODY RADIATION;

EID: 77955265949     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp596     Document Type: Article

References (29)

1. Rapaport AP, Miller Watelet LF, Linder T et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 1999; 17: 2446-2453.
2. Sonis ST, Oster G, Fuchs H et al. Oral mucositis and the clinical and economic outcomes of haematopoetic stem-cell transplantation. J Clin Oncol 2001; 19: 2201-2205.
3. Elting LS, Cooksley C, Chambers M et al. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98: 1531-1539.
4. Sonis ST, Elting LS, Keefe D et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement epidemiology, and consequences for patients. Cancer 2004; 100: 1995-2025.
5. National Cancer Institute. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: National Cancer Institute. 2006.
6. World Health Organization. Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: WHO Offset Publication No. 48. 1997.
7. Quinn B, Potting CM, Stone R et al. Guidelines for the assessment of oral mucositis in adult chemotherapy, radiotherapy and haematopoietic stem cell transplant patients. Eur J Cancer 2008; 44(1): 61-72.
8. Fallows G, Rubinger M, Bernstein CN. Does gastroenterology consultation change management of patients receiving hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 289-294.
9. Blijlevens NMA, Donnelly JP, Pauw BE. Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant. Bone Marrow Transplant 2005; 35: 707-711.
10. Keefe DM. Intestinal mucositis: mechanisms and management. Curr Opin Oncol 2007; 19(4): 323-327.
11. Crenn P, Vahedi K, Lavergne-Slove A et al. Plasma citrulline: a marker of enterocyte mass in villous atrophy-associated small bowel disease. Gastroenterology 2003; 124: 1210-1219.
12. Blijlevens NMA, Lutgens LCHW, Schattenberg AVMB, Donnelly JP. Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplant 2004; 34(3): 193-196.
13. Lutgens LC, Deutz NE, Geuelette J et al. Citrulline: a physiologic marker enabling quantification and monitoring of epithelial radiation-induced small bowel damage. Int J Radiat Oncol Biol Phys 2003; 57(4): 1067-1074.
14. Crenn P, De Truchis P, Neveux N et al. Plama citrulline is a biomarker of enterocyte mass and an indicator of parenteral nutrition in HIV-infected patients. Am J Clin Nutr 2009; 90: 587-594.
15. Crenn P, Coudray-Lucas C, Thuillier F et al. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology 2000; 119(6): 1496-1505.
16. David AI, Selvaggi G, Ruiz P et al. Blood citrulline level is an exclusionary marker for significant acute rejection after intestinal transplantation. Transplantation 2007; 84(9): 1077-1081.
17. Keefe D, Brealey J, Goland G, Cummins A. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000; 47(5): 632-637.
18. Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin Nutr 2008; 27(3): 328-339.
19. Ceballos I, Chauveau P, Guerin V et al. Early alterations of plasma free amino acids in chronic renal failure. Clin Chim Acta 1990; 188: 101-108.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
21. Wardley AM, Jayson GC, Swindell R et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haematopoietic progenitor rescue. Br J Haematol 2000; 110: 292-299.
22. Van Eijk HM, Rooyakkers DR, Deutz NE. Rapid routine determination of amino acids in plasma by high-performance liquid chromatography with a 2-3 microns Spherisorb ODS II column. J Chromatogr 1993; 620: 143-148.
23. Lutgens LC, Blijlevens NM, Deutz NE et al. Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer 2005; 103: 191-199.
24. Rhoads JM, Plunkett E, Galanko J et al. Serum citrulline levels correlate with enteral tolerance and bowel length in infants with short bowel syndrome. J Pediatr 2005; 146(4): 542-547.
25. Sonis ST, Eilers JP, Epstein JB et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiotherapy or chemotherapy. Cancer 1999; 85(10): 2103-2113.
26. Herbers AH, Blijlevens NM, Donnelly JP, de Witte TJ. Bacteraemia coincides with low citrulline concentrations after high-dose melphalan in autologous HSCT recipients. Bone Marrow Transplant 2008; 42(5): 345-349.
27. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia. Risks, consequences and new directions for its management. Cancer 2004; 100: 228-237.
28. Ellis M, Zwaan F, Hedstrom U et al. Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. Lancet 2003; 25: 275-280.
29. Spielberger R, Stiff P, Bensinger W et al. Palifermin for oral mucositis after intensive therapy for hematologic cancer. N Engl J Med 2004; 351: 2590-2598.